News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Category: Insider Information

Centers for Medicare & Medicaid Services open NCD review process for Epi proColon

Epigenomics AG / Key word(s): MiscellaneousCenters for Medicare & Medicaid Services open NCD review process for Epi proColon 28-Feb-2020 / 23:02 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.The issuer is solely responsible for the content of […]

Read more

Epigenomics AG successfully completes capital increase

Epigenomics AG / Key word(s): Capital Increase/Corporate ActionEpigenomics AG successfully completes capital increase 07-Nov-2019 / 23:36 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.The issuer is solely responsible for the content of this announcement. NOT FOR PUBLICATION, […]

Read more

Epigenomics AG sets subscription price at EUR 1.11 per new share

Epigenomics AG / Key word(s): Capital Increase/Corporate ActionEpigenomics AG sets subscription price at EUR 1.11 per new share 31-Oct-2019 / 09:31 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.The issuer is solely responsible for the content of […]

Read more

Epigenomics AG decides to increase share capital through rights issue with subscription rights of existing shareholders

Epigenomics AG / Key word(s): Capital Increase/Corporate ActionEpigenomics AG decides to increase share capital through rights issue with subscription rights of existing shareholders 17-Oct-2019 / 08:51 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.The issuer is solely […]

Read more

Epigenomics AG: Chinese Patent Reexamination Department partially invalidates Epigenomics’ patent claims for Septin9

Epigenomics AG / Key word(s): Patent/Legal MatterEpigenomics AG: Chinese Patent Reexamination Department partially invalidates Epigenomics’ patent claims for Septin9 15-Jul-2019 / 15:49 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.The issuer is solely responsible for the content […]

Read more

Epigenomics AG: CMS accepts Epigenomics’ application for NCD review

Epigenomics AG / Key word(s): MiscellaneousEpigenomics AG: CMS accepts Epigenomics’ application for NCD review 03-May-2019 / 00:40 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.The issuer is solely responsible for the content of this announcement. CMS accepts […]

Read more